Seagen

Youtube Subscribe

Open: 194.66 Close: 194.68 Change: 0.02

Don't invest before reading what an AI found about Seagen Company Inc Stock.

This document will help you to evaluate Seagen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, Inc, Federal, Trade, acquisition, IT, Manufacturing, and the …

Concept Map

Semantic Network

Stock Summary

Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors. It has collaboration agreements with Takeda.

Today's Summary

Seagen stock last closed at $194.68, down 0.16% from the previous day, and has increased 11.86% in one year. Seagen has a fifty-two week low of $116.08 and a 50-two-week high of $207.08. Pfizer is putting in every effort to get the Federal Trade Commissions approval for its proposed $43 billion acquisition.

Today's News

Seagen Inc. is a biotechnology company that discovers, develops, and commercializes transformative medicines for treating cancer. Pfizer is putting in every effort to get the Federal Trade Commissions approval for its proposed $43 billion acquisition of Seagen. Seagen could contribute roughly $10 billion in annual sales. Federal Trade Commission is asking for more information regarding Pfizers planned $43 billion acquisition of Seagen. Associate Director IT Manufacturing - Launchpad is responsible for IT in Seagens Manufacturing Sites. Seagen reports data from sea-cd40 in combination with other therapies in metastatic pancreatic ductal adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Increases Holdings in Seagen Inc.: A Promising Venture into the Biotechnology Sector Date: August 10, 2023. William Blair cut their Q3 2023 earnings estimates for shares of Seagen in a research report issued on Wednesday, August 2nd. The consensus estimate for Seagens current full-year earnings is ($3.21) per share. Seagen has a fifty-two week low of $116.08 and a 50-two-week high of $207. Seagen stock last closed at $194.68, down 0.16% from the previous day, and has increased 11.86% in one year.

Stock Profile

"Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington."

Keywords

The game is changing. There is a new strategy to evaluate Seagen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, Inc, Federal, Trade, acquisition, IT, Manufacturing, and the most common words in the summary are: seagen, stock, market, inc, best, news, company, . One of the sentences in the summary was: Seagen stock last closed at $194.68, down 0.16% from the previous day, and has increased 11.86% in one year. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #seagen #stock #market #inc #best #news #company.

Read more →

Youtube Subscribe

---